35. (Bevacizumab-Related Exclusion) Clinically significant (i.e. active) cardiovascular disease, for example cerebrovascular accidents </= 6 months prior to study enrolment, myocardial infarction </= 6 months prior to study enrollment, unstable angina, Grade II or greater congestive heart failure, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with protocol treatment.